| A decision chart for assessing and improving the transferability of economic evaluation results between countries R Welte, T Feenstra, H Jager, R Leidl Pharmacoeconomics 22, 857-876, 2004 | 336 | 2004 |
| Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison S Neubauer, R Welte, A Beiche, HH Koenig, K Buesch, R Leidl Tobacco control 15 (6), 464-471, 2006 | 271 | 2006 |
| Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology SS Tan, J Bakker, ME Hoogendoorn, A Kapila, J Martin, A Pezzi, G Pittoni, ... Value in Health 15 (1), 81-86, 2012 | 190 | 2012 |
| Health economics of infectious diseases R Welte, R Leidl, W Greiner, M Postma Modern Infectious Disease Epidemiology, 249-275, 2009 | 175* | 2009 |
| The costs of health damage and productivity losses attributable to cigarette smoking in Germany R Welte, HH König, R Leidl The European Journal of Public Health 10 (1), 31-38, 2000 | 160 | 2000 |
| Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections M Kretzschmar, R Welte, A Van den Hoek, MJ Postma American journal of epidemiology 153 (1), 90-101, 2001 | 159 | 2001 |
| Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach R WELTE, M KRETZSCHMAR, R LEIDL, A VAN DEN HOEK, JC JAGER, ... Sexually transmitted diseases 27 (9), 518-529, 2000 | 133 | 2000 |
| Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands JM Bos, H Rümke, R Welte, MJ Postma Clinical therapeutics 25 (10), 2614-2630, 2003 | 81 | 2003 |
| Costs and effects of chlamydial screening: dynamic versus static modeling R Welte, M Postma, R Leidl, M Kretzschmar Sexually transmitted diseases 32 (8), 474-483, 2005 | 71 | 2005 |
| Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis infections B Andersen, J Gundgaard, M Kretzschmar, J Olsen, R Welte, ... Sexually transmitted diseases 33 (7), 407-415, 2006 | 53 | 2006 |
| Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making R Welte, G Van den Dobbelsteen, JM Bos, H de Melker, L van Alphen, ... Vaccine 23 (4), 470-479, 2004 | 53 | 2004 |
| Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model C Dolk, M Eichner, R Welte, A Anastassopoulou, LA Van Bellinghen, ... Pharmacoeconomics 34, 1299-1308, 2016 | 51 | 2016 |
| The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine R Welte, CL Trotter, WJ Edmunds, MJ Postma, P Beutels Pharmacoeconomics 23, 855-874, 2005 | 44 | 2005 |
| Übertragung der Ergebnisse ökonomischer Evaluationsstudien aus dem Ausland auf Deutschland: Probleme und Lösungsansätze. R Welte, R Leidl Ansätze und Methoden der ökonomischen Evaluation: eine internationale …, 1999 | 42* | 1999 |
| Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program JM Bos, HC Rümke, R Welte, MJ Postma, JC Jager Vaccine 20 (1-2), 202-207, 2001 | 39 | 2001 |
| Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review O Damm, J Witte, S Wetzka, C Prosser, S Braun, R Welte, W Greiner International Journal of Public Health 61, 847-860, 2016 | 38 | 2016 |
| Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis MJ Postma, R Welte, JAR Van Den Hoek, GJJ Van Doornum, ... Value in Health 4 (3), 266-275, 2001 | 32 | 2001 |
| Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland U Siebert, C Behrend, N Mühlberger, J Wasem, W Greiner, ... Approaches and methods of economic evaluation in health care-an …, 1999 | 29 | 1999 |
| Cost impact of prospective HLA-B* 5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany E Wolf, M Blankenburg, JR Bogner, W Becker, D Gorriahn, MC Mueller, ... European journal of medical research 15, 145-151, 2010 | 28 | 2010 |
| Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands GA de Wit, EAB Over, BV Schmid, JEAM van Bergen, IVF van den Broek, ... Sexually Transmitted Infections 91 (6), 423-429, 2015 | 26 | 2015 |
Maarten PostmaProfessor in PharmacoEonomicsVerified email at rug.nl
